The information highlighted (if any) are the most recent updates for this brand.
Lorlak is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after previously treated with one or more ALK tyrosine kinase inhibitors (TKIs).